Die medikamentöse Therapie der Patientin mit Endometriose

Subscribe to RSS DOI: 10.1055/s-0042-122581 Die medikamentöse Therapie der Patientin mit Endometriose Authors Publication History Publication Date: 10 April 2017 (online) Symptome und Ausprägung einer Endometrioseerkrankung können vielschichtig sein. Therapeutisch steht die operative Resektion der Endometrioseläsionen im Vordergrund. Prä- und postoperativ ist eine medikamentöse Therapie zu diskutieren, in individuellen Fällen auch ohne vorherige histologische Sicherung. Zu beachten ist der Off-Label-Use bestimmter medikamentöser Therapien bei oftmals geringer Datenlage. Finden sich endometriale Zellen außerhalb des Cavum uteri, resultiert eine Endometriose mit zum Teil vielfältiger Beschwerdesymptomatik. Die Endometriose ist häufig chronisch und tritt mit einer Prävalenz von 4–30 % bei Frauen im gebärfähigen Alter auf; etwa die Hälfte der Frauen mit Fertilitätsproblematik ist davon betroffen. Aufgrund der Vielfalt der Symptome, die häufig weder mit dem Schweregrad noch mit der Lokalisation der Endometrioseläsionen korrelieren, steht die Laparoskopie mit histologischer Abklärung im Zentrum der Diagnostik. Als therapeutischer Goldstandard bei gesicherter Diagnose gilt die operative Entfernung der Endometrioseherde, ggf. prä- und postoperativ flankiert von einer medikamentösen Therapie. Unter Umständen kann auch eine alleinige medikamentöse Therapie erfolgen. Die medikamentösen Optionen zur Therapie der Endometriose werden mit folgender Zielsetzung eingesetzt: - Linderung der Schmerzen - Erhöhung der Schwangerschaftsraten - Reduktion der Rezidivraten Dies funktioniert meist nur in Kombination mit einer oder mehreren sanierenden Operationen. Vieles, wie die postoperative Rezidivprophylaxe oder die kontinuierliche Einnahme kombinierter Kontrazeptiva, ist durch prospektive randomisierte Vergleichsstudien unzureichend belegt. Auch unter einer medikamentösen Rezidivprophylaxe nach sanierender „R0“-Operation ist die Neigung des Wiederauftretens der Beschwerden hoch. - Literatur - 1 Knapp V. How old is endometriosis? Late 17th- and 18th century European descriptions of the disease. Fertil Steril 1999; 72: 10-14 - 2 Mahmood TA, Templeton A. Prevalence and genesis of endometriosis. Hum Reprod 1991; 6: 544-549 - 3 Moen MH, Schei B. Epidemiology of endometriosis in a Norwegian county. Acta Obstet Gynecol Scand 1997; 76: 559-562 - 4 Viganò P, Parazzini F, Somigliana E. et al. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol 2004; 18: 177-200 - 5 Witz CA, Burns WN. Endometriosis and infertility: is there a cause and effect relationship?. Gynecol Obstet Invest 2002; 53 (Suppl. 01) 2-11 - 6 Simpson JL, Elias S, Malinak LR. et al. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 1980; 137: 327-331 - 7 Renner SP, Strick R, Oppelt P. et al. Evaluation of clinical parameters and estrogen receptor alpha gene polymorphisms for patients with endometriosis. Reproduction 2006; 131: 153-161 - 8 Sallam HN, Garcia-Velasco JA, Dias S. et al. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006; (01) CD004635 - 9 Walter AJ, Hentz JG, Magtibay PM. et al. Endometriosis: correlation between histologic and visual findings at laparoscopy. Am J Obstet Gynecol 2001; 184: 1407-1411 discussion 1411–1413 - 10 Ulrich U, Nawroth F, Dorn C. Endometriose, Klinik, Diagnostik und Therapie. In: Ludwig M. Gynäkologische Endokrinologie und Reproduktionsmedizin. München: Hans Marseille; 2010: 219-227 - 11 Abbott J, Hawe J, Hunter D. et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004; 82: 878-884 - 12 Garry R. The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol 2004; 16: 299-303 - 13 Ulrich U, Buchweitz O, Greb R. et al. National German guideline (S2k): Guideline for the diagnosis and treatment of endometriosis: long version – AWMF Registry No. 015-045. Geburtshilfe Frauenheilkd 2014; 74: 1104-1118 - 14 Dunselman GA, Vermeulen N, Becker C. et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29: 400-412 - 15 Treloar SA, Bell TA, Nagle CM. et al. Early menstrual characteristics associated with subsequent diagnosis of endometriosis. Am J Obstet Gynecol 2010; 202: 534.e1-534.e6 - 16 Missmer SA, Hankinson SE, Spiegelman D. et al. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol 2004; 104: 965-974 - 17 Hediger ML, Hartnett HJ, Louis GM. Association of endometriosis with body size and figure. Fertil Steril 2005; 84: 1366-1374 - 18 Parazzini F, La Vecchia C, Franceschi S. et al. Risk factors for endometrioid, mucinous and serous benign ovarian cysts. Int J Epidemiol 1989; 18: 108-112 - 19 Nouri K, Ott J, Krupitz B. et al. Family incidence of endometriosis in first-, second-, and third-degree relatives: case-control study. Reprod Biol Endocrinol 2010; 8: 85 - 20 Harada T, Momoeda M, Taketani Y. et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90: 1583-1588 - 21 Kirshon B, Poindexter 3rd AN. Contraception: a risk factor for endometriosis. Obstet Gynecol 1988; 71: 829-831 - 22 Strathy JH, Molgaard CA, Coulam CB. et al. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil Steril 1982; 38: 667-672 - 23 Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ 1993; 306: 182-184 - 24 Allen C, Hopewell S, Prentice A. et al. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2009; (02) CD004753 - 25 Allen C, Hopewell S, Prentice A. Non-steroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2005; (04) CD004753 - 26 Kennedy S, Bergqvist A, Chapron C. et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698-2704 - 27 Marjoribanks J, Proctor M, Farquhar C. et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; (01) CD001751 - 28 WHO. Scoping Document for WHO Guidelines for the pharmacological treatment of persisting pain in adults with medical illnesses. 2012 Im Internet: http://www.who.int/medicines/areas/quality_safety/guide_on_pain/en/ Stand: 20.01.2017 - 29 Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; (12) CD008475 - 30 Guzick DS, Huang LS, Broadman BA. et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011; 95: 1568-1573 - 31 Zupi E, Marconi D, Sbracia M. et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 2004; 82: 1303-1308 - 32 Davis L, Kennedy SS, Moore J. et al. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; (03) CD001019 - 33 Vercellini P, Frontino G, De Giorgi O. et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80: 560-563 - 34 Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2001; (04) CD002120 - 35 Göretzlehner G. Menstrual bleeding – must that be? Extended use of oral hormonal contraception. Zentralbl Gynakol 2005; 127: 302-307 - 36 Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89-96 - 37 Mahutte NG, Arici A. Medical management of endometriosis-associated pain. Obstet Gynecol Clin North Am 2003; 30: 133-150 - 38 BfArM. Medizinprodukte. Venöse Thromboembolien und kombinierte hormonale Kontrazeptiva. 2016 Im Internet: http://www.bfarm.de/DE/Arzneimittel/Pharmakovigilanz/KOK/_node.html/ Stand: 20.01.2017 - 39 Ludwig M. Kontrazeption – ab wann und wie lange?. Gynäkologe 2015; 48: 634-642 - 40 Vercellini P, Barbara G, Somigliana E. et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93: 2150-2161 - 41 Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2000; (02) CD002122 - 42 Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2012; (03) CD002122 - 43 Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988; 72: 323-327 - 44 Telimaa S, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecol Endocrinol 1987; 1: 363-371 - 45 Strowitzki T, Faustmann T, Gerlinger C. et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010; 151: 193-198 - 46 Petraglia F, Hornung D, Seitz C. et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2012; 285: 167-173 - 47 Strowitzki T, Marr J, Gerlinger C. et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010; 25: 633-641 - 48 Kohler G, Faustmann TA, Gerlinger C. et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010; 108: 21-25 - 49 Andres Mde P, Lopes LA, Baracat EC. et al. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet 2015; 292: 523-529 - 50 Vercellini P, Bracco B, Mosconi P. et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 2016; 105: 734-743.e3 - 51 Klipping C, Duijkers I, Remmers A. et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol 2012; 52: 1704-1713 - 52 Vercellini P, Vigano P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol 2005; 17: 359-365 - 53 Petta CA, Ferriani RA, Abrao MS. et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 2005; 20: 1993-1998 - 54 Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012; 97: 616-622 - 55 Schweppe KW. Guidelines for the use of GnRH-analogues in the treatment of endometriosis. Zentralbl Gynakol 2005; 127: 308-313 - 56 Sagsveen M, Farmer JE, Prentice A. et al. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; (04) CD001297 - 57 Hornstein MD, Surrey ES, Weisberg GW. et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91: 16-24 - 58 Hornstein M, Gibbons W. Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists. 04.10.2016 Im Internet: https://www.uptodate.com Stand: 20.01.2017 - 59 Busacca M, Somigliana E, Bianchi S. et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III—IV: a randomized controlled trial. Hum Reprod 2001; 16: 2399-2402 - 60 Hornstein MD, Yuzpe AA, Burry KA. et al. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 1995; 63: 955-962 - 61 Vercellini P, Crosignani PG, Fadini R. et al. A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol 1999; 106: 672-677 - 62 Hornstein MD, Hemmings R, Yuzpe AA. et al. Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 1997; 68: 860-864 - 63 Strowitzki T, Thoene C, von Wolff M. Medikamentöse Behandlung der Endometriose. Journal für Fertilität und Reproduktion 2003; 3: 13-18 - 64 Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006; 12: 49-56 - 65 Ebert AD, Bartley J, David M. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions – old answers?. Eur J Obstet Gynecol Reprod Biol 2005; 122: 144-150 - 66 Ferrero S, Gillott DJ, Venturini PL. et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol 2011; 9: 89 - 67 Nawathe A, Patwardhan S, Yates D. et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. Br J Obstet Gynaecol 2008; 115: 818-822 - 68 Rose PG, Alvarez B, Maclennan GT. Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure. Am J Obstet Gynecol 2000; 183: 507-508 - 69 Altintas D, Kokcu A, Kandemir B. et al. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol 2010; 150: 84-87 - 70 Stratton P, Sinaii N, Segars J. et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 2008; 111: 88-96 - 71 Merviel P, Lourdel E, Sanguin S. et al. Interest of selective progesterone receptor modulators in endometriosis. Gynecol Obstet Fertil 2013; 41: 524-528 - 72 Kupker W, Felberbaum RE, Krapp M. et al. Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 2002; 5: 12-16 - 73 Diamond MP, Carr B, Dmowski WP. et al. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study. Reprod Sci 2014; 21: 363-371 - 74 Carr B, Dmowski WP, OʼBrien C. et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci 2014; 21: 1341-1351 - 75 Hughes E, Brown J, Collins JJ. et al. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2007; (03) CD000155 - 76 Deaton JL, Gibson M, Blackmer KM. et al. A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. Fertil Steril 1990; 54: 1083-1088 - 77 Tummon IS, Asher LJ, Martin JS. et al. Randomized controlled trial of superovulation and insemination for infertility associated with minimal or mild endometriosis. Fertil Steril 1997; 68: 8-12 - 78 Werbrouck E, Spiessens C, Meuleman C. et al. No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women with unexplained infertility after controlled ovarian hyperstimulation and intrauterine insemination. Fertil Steril 2006; 86: 566-571 - 79 Benaglia L, Somigliana E, Santi G. et al. IVF and endometriosis-related symptom progression: insights from a prospective study. Hum Reprod 2011; 26: 2368-2372 - 80 Benaglia L, Somigliana E, Vercellini P. et al. The impact of IVF procedures on endometriosis recurrence. Eur J Obstet Gynecol Reprod Biol 2010; 148: 49-52 - 81 Coccia ME, Rizzello F, Gianfranco S. Does controlled ovarian hyperstimulation in women with a history of endometriosis influence recurrence rate?. J Womens Health (Larchmt) 2010; 19: 2063-2069 - 82 Donnez J, Nisolle M, Gillet N. et al. Large ovarian endometriomas. Hum Reprod 1996; 11: 641-646 - 83 Muzii L, Marana R, Caruana P. et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on laparoscopic excision of ovarian endometriotic cysts. Fertil Steril 1996; 65: 1235-1237 - 84 Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update 1998; 4: 312-322 - 85 Bragheto AM, Caserta N, Bahamondes L. et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007; 76: 195-199 - 86 Fedele L, Bianchi S, Raffaelli R. et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997; 68: 426-429 - 87 Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999; 60: 173-175 - 88 Kitawaki J. Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol 2006; 20: 493-502 - 89 Sheng J, Zhang WY, Zhang JP. et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009; 79: 189-193 - 90 Renner SP, Rix S, Boosz A. et al. Preoperative pain and recurrence risk in patients with peritoneal endometriosis. Gynecol Endocrinol 2010; 26: 230-235 - 91 Renner SP, Lermann J, Hackl J. et al. Chronische Erkrankung. Endometriose. Geburtshilfe Frauenheilkd 2012; 72: 914-919 - 92 Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev 2004; (03) CD003678 - 93 Abou-Setta AM, Houston B, Al-Inany HG. et al. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev 2013; (01) CD005072 - 94 Vercellini P, Somigliana E, Viganò P. et al. Post-operative endometriosis recurrence: a plea for prevention based on pathogenetic, epidemiological and clinical evidence. Reprod Biomed Online 2010; 21: 259-265 - 95 Seracchioli R, Mabrouk M, Manuzzi L. et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod 2009; 24: 2729-2735 - 96 Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292: 37-43